T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. - Wikidata - awgldk - TriplyDB

T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer.

T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer.

http://www.wikidata.org/entity/Q30832820

about

Multi-omics study revealing the complexity and spatial heterogeneity of tumor-infiltrating lymphocytes in primary liver carcinoma.Cervical Cancer Neoantigen Landscape and Immune Activity is Associated with Human Papillomavirus Master Regulators.Progressive hypoventilation due to mixed CD8+ and CD4+ lymphocytic polymyositis following tremelimumab - durvalumab treatment.An engineered protein antagonist of K-Ras/B-Raf interaction.Tools to define the melanoma-associated immunopeptidome.Immunotherapy for pancreatic cancer: present and future.HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model.Immune targets and neoantigens for cancer immunotherapy and precision medicine.Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer.Applications of Immunogenomics to Cancer.Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations.Targeting neoantigens to augment antitumour immunity.The Heterocellular Emergence of Colorectal Cancer Mechanisms of Resistance in Multiple Myeloma.Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment.Tuning cancer fate: the unremitting role of host immunity.Dendritic Cell Strategies for Eliciting Mutation-Derived Tumor Antigen Responses in Patients.CARs: Synthetic Immunoreceptors for Cancer Therapy and Beyond.Harnessing the immune response to target tumors.Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy.Overcoming Oncogenic Mediated Tumor Immunity in Prostate Cancer.Immunotherapy in gastrointestinal cancers Immunotherapy: Hiding in plain sight: immune escape in the era of targeted T-cell-based immunotherapies.Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient.The Potential and Challenges of Exploiting the Vast But Dynamic Neoepitope Landscape for Immunotherapy.A Review of Immune Therapy in Cancer and a Question: Can Thermal Therapy Increase Tumor Response?Fall of the mutants: T cells targeting BCR-ABL.It's a long way to the top (if you want to personalize immunotherapy)Awakening immunity against cancer: a 2017 primer for clinicians.KRAS mutation and Consensus Molecular Subtypes 2 and 3 are independently associated with reduced immune infiltration and reactivity in colorectal cancer.'Hotspots' of Antigen Presentation Revealed by Human Leukocyte Antigen Ligandomics for Neoantigen Prioritization.An Efficient Single-Cell RNA-Seq Approach to Identify Neoantigen-Specific T Cell Receptors.Metastasectomy for Tumor-Infiltrating Lymphocytes: An Emerging Operative Indication in Surgical Oncology.Molecular genetics and cellular events of K-Ras-driven tumorigenesis.Human Pluripotent Stem Cells to Produce Cell-based Cancer Immunotherapy.Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy.Re-balance of memory T cell subsets in peripheral blood from patients with CML after TKI treatment.Identification and Characterization of Neoantigens As Well As Respective Immune Responses in Cancer Patients.Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution.

P2860

Q33798623-50513C1F-D9B1-4443-AA31-4CE30666CA12 Q33806351-1FB0E220-D266-48F9-ABB1-B2421497D134 Q33913077-9B3B2DA5-C286-4F38-B34C-1C7B3AA8E247 Q33918529-7B678939-61C9-499F-BD6B-1231FA94015B Q38650013-8D0968A9-CE75-4E99-B4E6-26DB3BE19887 Q38673158-D6971244-536C-4C77-835B-43C3CE7B6B77 Q38706874-47253A3B-DFDA-4CD7-96DF-FBA024D8DD87 Q39057617-C14D6B08-951E-4B59-8D5D-8E3E00369B92 Q39120155-653E5557-62C5-4840-A278-7A50938576FE Q39130420-F45D1D1F-02F5-4151-A728-D2200EB2C5C9 Q39130451-EAE80B7C-26CE-4F65-9DD8-AAA13A45753E Q39136403-9615422C-3AEF-4F09-B554-9E5C23983980 Q39149196-3191B3AE-1B01-49AD-9EE1-ECC34FA7B7E6 Q39152114-5A0E614C-7579-4B02-AFDA-0AABF785EDCB Q39185604-0DB402F6-1659-4D59-AE25-23ADDC5BFA6F Q39194733-431CE550-280B-4BEC-80B5-683E86AA3B9C Q39239026-175D15D8-50B6-4E79-9D51-7F18999B7751 Q39243064-D7510CBF-63D4-4905-9140-BE696831FC69 Q39246685-D0F8D819-8377-4236-8479-35AD7214E6C6 Q39377265-FF4E7139-2115-41D3-9CC4-15332597D528 Q39418546-568D09E7-3671-4D07-A89C-A2696E2C9E15 Q39438805-EBF6215F-E865-48A5-A0F8-A8728846A018 Q39453597-CE3EC669-828C-459F-94D2-59D6BEA8BCF7 Q41183874-9792EF7F-0362-4132-8BD7-1F0ED485F5D6 Q41571576-36794053-78E2-4EF3-B095-04C723A4BE69 Q41673084-01DF51A6-F1FD-4D86-995A-7C1CBE790EBD Q41928232-2A278E33-4E56-4004-BFDB-ABA12FE34ACC Q42324198-7502BD2A-133F-46CE-A2D2-03435EAB04B7 Q42330130-C79C3FD1-1214-48C3-A143-9947B0DCB702 Q42347636-4470088F-E48D-44C8-8E4E-BA56BDAC1482 Q42778262-E804DCF9-4EFC-45E5-BDDE-E18F5DF6B94A Q45718710-955A7DDC-D939-4D3F-BCF1-9BFA9C19F9F5 Q45875006-083A36D9-5DB9-410D-885C-5C1C72B54127 Q46056233-CF0842AE-9F2D-439F-8CEA-EBFDD7ACFE7D Q46277416-B4F28F1A-4512-4DF0-B726-038C93B24A5E Q46350666-90AF722B-BEB0-4282-A034-B4F89295F903 Q46512368-62281353-DCD3-4D96-A082-81E41B26D216 Q47124785-AF62B223-D71D-4747-90F8-F7751DD1954D Q47133741-B6D3C4E8-96D6-4119-9717-0734AD8E53C9 Q47150991-0EC60C58-EE1D-4886-B88C-A34212F969C6

P2860

T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer.

http://www.wikidata.org/entity/Q30832820

description

2016 nî lūn-bûn

@nan

2016 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer.

@ast

T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer.

@en

type

label

T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer.

@ast

T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer.

@en

prefLabel

T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer.

@ast

T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer.

@en

P1433

Q30832820-0864669F-C872-4989-8991-4EE2F6ADDACA

P1476

Q30832820-2DA01543-EBF7-4B0D-9F29-070ADFF5EEAB

P2093

Q30832820-1A7EE5E6-6074-48E1-A4F2-34731529D293

Q30832820-3304EE77-028C-46DD-AC4D-86BD1F6EE662

Q30832820-3F1127E6-C666-4EFE-8D72-82128B98936B

Q30832820-4D503C6F-3E41-4F34-A832-14B2240F59C1

Q30832820-5839835D-52C4-4125-A383-745310622FB9

Q30832820-63530717-587A-4674-9F89-ED0B3AE048D7

Q30832820-6CE85776-0DB2-418E-AFA0-DF007F396015

Q30832820-752E32C1-C227-4372-9E71-5695E9B166A4

Q30832820-81D1A854-9EB3-45AC-9C79-8197BF5964F6

Q30832820-EEFA7AEC-B9F7-4862-ADFC-E952A97AE410

P2860

Q30832820-129770A8-F351-43E0-8EFD-0794E497A70B

Q30832820-2011E0B5-9ACE-4C80-AEAB-1E7545F405ED

Q30832820-4199DF39-73FB-41D9-B74C-78E9A562C107

Q30832820-425C9E99-B823-4131-A2B3-3088D5A6A2B3

Q30832820-4C5F5C21-85B6-4E6B-B84D-8AB532E3620E

Q30832820-635A2822-44C8-4E42-AF93-4D12FA6F3282

Q30832820-6A94C95F-ABD2-4414-84D7-87525DDF039E

Q30832820-6B88C0FE-80AA-4E53-8C66-12429A09510D

Q30832820-6BBB17CA-DA5B-4489-924F-0DCC7D111055

Q30832820-73252072-F090-42AE-8B31-52FF18C1E22C

P304

Q30832820-4CF2952F-0067-4D31-87E0-788E90CB8554

P31

Q30832820-08CB35E2-7D41-4399-ADA6-A08889F572B4

P356

Q30832820-AE2AE3BC-9414-4B93-AC50-678DD8AFB0A7

P407

Q30832820-F217ECC2-036E-4E01-8EF9-EDE4AA38352B

P433

Q30832820-A712A973-0707-4384-8C55-798E7E25D4F4

P478

Q30832820-88E26C71-D794-4F30-8976-AC7792E4740F

P50

Q30832820-65E0A403-76FF-41C8-86E6-2908C7B835F4

P577

Q30832820-698B2EED-A2A7-436B-866C-F02F7E87DF45

P698

Q30832820-B4A2D99B-0B56-4C8B-99DB-EFD57C1AC826

P932

Q30832820-4EE7482C-24A5-437F-B949-2C58963E98E9

P356

P1433

The New England Journal of Medicine

P1476

T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer

@en

P2093

Anna Pasetto

http://www.w3.org/2001/XMLSchema#string

Eric M Groh

http://www.w3.org/2001/XMLSchema#string

Eric Tran

http://www.w3.org/2001/XMLSchema#string

Isaac R Kriley

http://www.w3.org/2001/XMLSchema#string

Jared J Gartner

http://www.w3.org/2001/XMLSchema#string

Li Jia

http://www.w3.org/2001/XMLSchema#string

Paul F Robbins

http://www.w3.org/2001/XMLSchema#string

Satyajit Ray

http://www.w3.org/2001/XMLSchema#string

Steven A Rosenberg

http://www.w3.org/2001/XMLSchema#string

Todd D Prickett

http://www.w3.org/2001/XMLSchema#string

P2860

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

The urgent need to recover MHC class I in cancers for effective immunotherapy

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

Genetic basis for clinical response to CTLA-4 blockade in melanoma

Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells

Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data.

Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions.

Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regression.

P304

2255-2262

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1609279

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

375

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27959684

http://www.w3.org/2001/XMLSchema#string

P932

5178827

http://www.w3.org/2001/XMLSchema#string